Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Published

Journal Article

Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. IL28B has been linked with LDL-C levels using a candidate gene approach, but it is not known whether other genetic variants are associated with LDL-C, nor how these factors definitively affect SVR. We assessed genetic predictors of serum lipid and triglyceride levels in 1604 patients with genotype 1 (G1) chronic hepatitis C virus (HCV) infection by genome-wide association study and developed multivariable predictive models of SVR. IL28B polymorphisms were the only common genetic variants associated with pretreatment LDL-C level in Caucasians (rs12980275, P = 4.7 × 10(-17), poor response IL28B variants associated with lower LDL-C). The association was dependent on HCV infection, IL28B genotype was no longer associated with LDL-C in SVR patients after treatment, while the association remained significant in non-SVR patients (P < 0.001). LDL-C was significantly associated with SVR for heterozygous IL28B genotype patients (P < 0.001) but not for homozygous genotypes. SVR modelling suggested that IL28B heterozygotes with LDL-C > 130 mg/dL and HCV RNA ≤600 000 IU/mL may anticipate cure rates >80%, while the absence of these two criteria was associated with an SVR rate of <35%. IL28B polymorphisms are the only common genetic variants associated with pretreatment LDL-C in G1-HCV. LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy.

Full Text

Duke Authors

Cited Authors

  • Clark, PJ; Thompson, AJ; Zhu, M; Vock, DM; Zhu, Q; Ge, D; Patel, K; Harrison, SA; Urban, TJ; Naggie, S; Fellay, J; Tillmann, HL; Shianna, K; Noviello, S; Pedicone, LD; Esteban, R; Kwo, P; Sulkowski, MS; Afdhal, N; Albrecht, JK; Goldstein, DB; McHutchison, JG; Muir, AJ; IDEAL investigators,

Published Date

  • May 2012

Published In

Volume / Issue

  • 19 / 5

Start / End Page

  • 332 - 340

PubMed ID

  • 22497812

Pubmed Central ID

  • 22497812

Electronic International Standard Serial Number (EISSN)

  • 1365-2893

International Standard Serial Number (ISSN)

  • 1352-0504

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2893.2011.01553.x

Language

  • eng